Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies (Details Textual)

v3.7.0.1
Commitments and Contingencies (Details Textual) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended
Jan. 14, 2014
Dec. 31, 2015
Mar. 31, 2017
Mar. 31, 2016
Mar. 31, 2017
Mar. 31, 2016
Jun. 30, 2015
Sep. 01, 2014
Dec. 30, 2013
Apr. 30, 2013
Commitments and Contingencies [Line Items]                    
Research and Development Expense, Total     $ 1,136,000 $ 1,048,000 $ 3,005,000 $ 2,303,000        
Royalty Guarantees, Commitments, Amount     200,000   $ 200,000          
Long Term Purchase Commitment Expire Date         Dec. 31, 2015          
Commitments [Member]                    
Commitments and Contingencies [Line Items]                    
Research Services Agreements Value Fulfilling Commitment   $ 3,000,000                
Research and Development Expense, Total             $ 2,700,000      
License Costs $ 30,627                  
Initial license fee 20,000                  
Contractual Obligation, Due in Next Twelve Months                 $ 78,000  
Contractual Obligation, Due in Second Year               $ 161,754    
Settlement Agreement [Member]                    
Commitments and Contingencies [Line Items]                    
Prepaid Expense                   $ 1,000,000
Amended Agreement [Member]                    
Commitments and Contingencies [Line Items]                    
Research and Development Expense, Total             $ 2,100,000      
Minimum [Member] | Commitments [Member]                    
Commitments and Contingencies [Line Items]                    
License Costs 25,000                  
Maximum [Member] | Commitments [Member]                    
Commitments and Contingencies [Line Items]                    
License Costs $ 150,000                  
Fraunhofer [Member]                    
Commitments and Contingencies [Line Items]                    
Royalty Guarantees, Commitments, Amount     $ 4,000,000   $ 4,000,000          
Other Commitments, Description         under the terms of the TTA and for a period of 15 years, the Company shall pay Fraunhofer one percent (1%) of all receipts derived by the Company from sales of products produced utilizing the iBioLaunch or iBioModulator technology and ten percent (10%) of all receipts derived by the Company from licensing either of those technologies to third parties.